Our vision is to improve the lives of those affected by respiratory diseases and those who provide care to them.
Last year, we celebrated 100 years of innovation in the field of aerosol science and inhalation technology.
PARI is made up of a worldwide network of companies, each with a specific focus in developing or improving aerosol therapies. We dominate the field of liquid drug aerosol delivery by nebulizer.
PARI products are considered the “Gold Standard” for new nebulized medications being developed and used in clinical trials. Pharmaceutical companies with approved medications using PARI products include:
- Accuneb® (Dey) for asthma
- Brovana® (Sepracor) for COPD
- Cayston® (Gilead) for CF
- DuoNeb® (Dey) for COPD, asthma
- Perforomist® (Dey) for COPD
- Pulmicort® Respules (AstraZeneca) for asthma
- Pulmozyme® (Genentech) for cystic fibrosis
- TOBI® (Novartis) for cystic fibrosis
- Xopenex® (Sepracor) for asthma
Currently, PARI products are being used in 15 additional clinical trials in the development of new nebulized treatments.